Answers are grounded in this paper and cite their sources.
PURPOSE OF REVIEW: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have emerged as a leading pharmacologic for managing weight gain across most populations, including peri and postmenopausal women who frequently suffer from weight gain. There is a paucity of data about this specific population and how they respond to these medications. This review aims to discuss the data available about the use and effects of GLP-1 RAs in the peri and postmenopausal populations. RECENT FINDINGS: GLP-1 RAs are consistently the most effective pharmacologic for weight loss and can be a valuable tool for use in peri and postmenopausal women. SUMMARY: Additional research is needed to determine the risks and benefits and ideal use of GLP-1 RAs in peri and postmenopausal women.
No takes yet. Share an insight, caveat, or question.
Mikdachi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: